{"id":607539,"date":"2022-07-11T18:32:01","date_gmt":"2022-07-11T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=607539"},"modified":"2022-07-11T18:32:01","modified_gmt":"2022-07-11T18:32:01","slug":"sarcoidosis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-united-therapeutics-atyr-pharma-actelion-janssen-bellerophon-therapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sarcoidosis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-united-therapeutics-atyr-pharma-actelion-janssen-bellerophon-therapeutics-and-others_607539.html","title":{"rendered":"Sarcoidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies &#8211; United Therapeutics, aTyr Pharma, Actelion, Janssen, Bellerophon Therapeutics, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sarcoidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies - United Therapeutics, aTyr Pharma, Actelion, Janssen, Bellerophon Therapeutics, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Sarcoidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies - United Therapeutics, aTyr Pharma, Actelion, Janssen, Bellerophon Therapeutics, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Sarcoidosis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sarcoidosis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Sarcoidosis market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Sarcoidosis Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/8adb56e97a6968917803532df8d33819.jpg\" alt=\"Sarcoidosis Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Sarcoidosis is a systemic disease of unknown cause that is characterized by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system.<\/p>\n<p style=\"text-align: justify;\">Sarcoidosis is a global disease, with a prevalence of about <strong>4&middot;7&ndash;64 in 100 000<\/strong>, and an incidence of <strong>1&middot;0&ndash;35&middot;5 in 100 000 per year<\/strong>. The highest rates are reported in northern European and African&ndash;American individuals, particularly in women, and the lowest in Japan. Differences in prevalence and incidence are linked to age, sex, ethnic origin, and geographical location.<\/p>\n<p style=\"text-align: justify;\"><em>Clinical expression of sarcoidosis is affected by epidemiological and socioeconomic factors. Elderly-onset sarcoidosis is much more common in women, and in this disorder, there is an increased rate of change in general health and extrapulmonary manifestations, particularly uveitis.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In a study using the Optum health insurance medical claims database in the USA, the incidence rate ranged from <strong>7.6 to 8.8 per 100,000 per year<\/strong>. African Americans had a higher incidence and prevalence compared with Caucasians, Hispanics, and Asians.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A recent study from the Italian province of Parma reported a prevalence of <strong>0.05%<\/strong>, which varied by residential location from 0.03% to 0.09% (Beghe et., al 2017).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to DelveInsight&rsquo;s analysis, Sarcoidosis is more prominent in females in comparison to males.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sarcoidosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Sarcoidosis Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>As per DelveInsight, the Sarcoidosis Market size is expected to grow in the coming years owing to the increase in the understanding of Sarcoidosis, increasing prevalence, and the expected launch of novel therapies, such as Selexipag, and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Sarcoidosis market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Sarcoidosis market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Diagnosed Prevalent cases of Sarcoidosis&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific cases of Sarcoidosis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age-specific cases of Sarcoidosis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Sarcoidosis market<\/strong> or expected to get launched during the study period. The analysis covers Sarcoidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Sarcoidosis Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Sarcoidosis market has a promising outlook with the emerging therapies, mostly consisting of Phase II assets developed by global pharma and biotech companies.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Sarcoidosis Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Selexipag&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhaled nitric oxide (iNO)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ATYR1923&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhaled treprostinil&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Sarcoidosis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">United Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">aTyr Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bellerophon Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Actelion\/Janssen Pharmaceutical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Sarcoidosis Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Sarcoidosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Sarcoidosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Sarcoidosis Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Sarcoidosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Sarcoidosis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Sarcoidosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Sarcoidosis Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Sarcoidosis Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Sarcoidosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Sarcoidosis Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Sarcoidosis Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Sarcoidosis Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Sarcoidosis Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Sarcoidosis Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Sarcoidosis Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/sarcoidosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Healthcare Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/kyphoscoliosis-market\">Kyphoscoliosis Market<br \/><\/a><\/strong>&#8220;Kyphoscoliosis Market&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Kyphoscoliosis Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sarcoidosis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-united-therapeutics-atyr-pharma-actelion-janssen-bellerophon-therapeutics-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sarcoidosis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-united-therapeutics-atyr-pharma-actelion-janssen-bellerophon-therapeutics-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Sarcoidosis Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sarcoidosis Market size, share, and trends in the seven major market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sarcoidosis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-united-therapeutics-atyr-pharma-actelion-janssen-bellerophon-therapeutics-and-others_607539.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,405,417,406],"tags":[],"class_list":["post-607539","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=607539"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607539\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=607539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=607539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=607539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}